The Food and Drug Administration has pushed backed its review date for a proposed blockbuster drug to treat lupus from GlaxoSmithKline (NYSE: GSK) and Human Genome Sciences (Nasdaq: HGSI).

The date had been set for Dec. 9.

The review will now take place in March, the companies announced Friday.

HGS said the FDA requested more information after a review by an FDA committee last month. That data has been submitted, the Maryland-based company said.

If approved, the drug could be worth billions of dollars a year in sales.

Read the announcement here.

GSK maintains its U.S. headquarters in Research Triangle Park.

Get the latest news alerts: Follow LTW at Twitter.